DPW
BCRX icon

DiNuzzo Private Wealth’s BioCryst Pharmaceuticals BCRX Stock Holding History

DiNuzzo Private Wealth’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-13
Closed -$67 – 1413
2024
Q1 		$67 Sell
13
-2
-13% -$11 ﹤0.01% 1316
2023
Q4 		$90 Buy
+15
New +$87 ﹤0.01% 1328

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

DiNuzzo Private Wealth's BCRX Position: Q2 2024 in Review

DiNuzzo Private Wealth sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2024, closing a stake of 13 shares — an estimated $67 sold.

DiNuzzo Private Wealth first reported a position in BCRX in Q4 2023 and held it in 2 quarters. The position peaked at $90 in Q4 2023. 241 funds tracked by Wall St. Rank hold BCRX as of Q2 2024.

  • DiNuzzo Private Wealth reported no remaining BioCryst Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • DiNuzzo Private Wealth sold 13 BioCryst Pharmaceuticals shares in Q2 2024, an estimated $67.
  • DiNuzzo Private Wealth first reported a position in BioCryst Pharmaceuticals in Q4 2023 and held it in 2 quarters.
  • DiNuzzo Private Wealth's BioCryst Pharmaceuticals position peaked at $90 in Q4 2023.
  • 241 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2024.

Based on DiNuzzo Private Wealth's 13F filing for Q2 2024, filed 30 Jul 2024.